Skip Navigation

JNCI Journal of the National Cancer Institute 2001 93(9):662-664; doi:10.1093/jnci/93.9.662
© 2001 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Abrams, J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Abrams, J. S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 93, No. 9, 662-664, May 2, 2001
© 2001 Oxford University Press

EDITORIAL

Tamoxifen: Five Versus Ten Years—Is the End in Sight?

Jeffrey S. Abrams

Affiliation of author: Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.

Correspondence to: Jeffrey S. Abrams, M.D., National Institutes of Health, 6130 Executive Blvd., EPN 7040, Bethesda, MD 20892 (e-mail: abramsj@ctep.nci.nih.gov).

This issue of the Journal updates a truly seminal study, the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 (1). For students of history, few clinical trials provide as many valuable lessons as B-14 does with regard to both hormone-responsive breast cancer treatment and clinical trials methodology. Initiated in 1981, it was the first placebo-controlled trial performed by the NSABP. A total of 2892 women with lymph node-negative, estrogen receptor (ER)-positive tumors were enrolled. By 1988, initial results indicated a disease-free survival (DFS) benefit for tamoxifen in this subset of women (2). More important, premenopausal and postmenopausal women benefited equally from tamoxifen in B-14, contrary to the predominant belief at the time that only postmenopausal women should receive adjuvant tamoxifen (3). The findings led to the issuance by the National Cancer Institute (NCI) (Bethesda, MD) of a clinical alert (4), with . . . [Full Text of this Article]

REFERENCES


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
C. C. Maley, B. J. Reid, and S. Forrest
Cancer Prevention Strategies That Address the Evolutionary Dynamics of Neoplastic Cells: Simulating Benign Cell Boosters and Selection for Chemosensitivity
Cancer Epidemiol. Biomarkers Prev., August 1, 2004; 13(8): 1375 - 1384.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. Martino, J. Costantino, M. McNabb, J. Mershon, K. Bryant, T. Powles, and R. J. Secrest
The Role of Selective Estrogen Receptor Modulators in the Prevention of Breast Cancer: Comparison of the Clinical Trials
Oncologist, April 1, 2004; 9(2): 116 - 125.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
B. L. Riggs and L. C. Hartmann
Selective Estrogen-Receptor Modulators -- Mechanisms of Action and Application to Clinical Practice
N. Engl. J. Med., February 13, 2003; 348(7): 618 - 629.
[Full Text] [PDF]

Home page
 JCOHome page
L. C. Harlan, J. Abrams, J. L. Warren, L. Clegg, J. Stevens, and R. Ballard-Barbash
Adjuvant Therapy for Breast Cancer: Practice Patterns of Community Physicians
J. Clin. Oncol., April 1, 2002; 20(7): 1809 - 1817.
[Abstract] [Full Text] [PDF]